Literature DB >> 22431866

Warfarin pharmacogenetics: a rising tide for its clinical value.

Julie A Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22431866      PMCID： PMC3337679          DOI： 10.1161/CIRCULATIONAHA.112.100628

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

Authors:  Jack Ansell; Jennifer Hollowell; Vittorio Pengo; Fernando Martinez-Brotons; Jaime Caro; Ludovic Drouet
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

3.  A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Scott C Woller; Kent M Samuelson; Justin W Mansfield; Michelle Robinson; Stephanie Barton; Kim Brunisholz; Chrissa P Mower; John A Huntinghouse; Jeffrey S Rollo; Dustin Siler; Tami L Bair; Stacey Knight; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2012-03-19       Impact factor: 29.690

4.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Authors:  Nita A Limdi; Mia Wadelius; Larisa Cavallari; Niclas Eriksson; Dana C Crawford; Ming-Ta M Lee; Chien-Hsiun Chen; Alison Motsinger-Reif; Hersh Sagreiya; Nianjun Liu; Alan H B Wu; Brian F Gage; Andrea Jorgensen; Munir Pirmohamed; Jae-Gook Shin; Guilherme Suarez-Kurtz; Stephen E Kimmel; Julie A Johnson; Teri E Klein; Michael J Wagner
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

Review 5.  New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.

Authors:  David A Garcia; Renato D Lopes; Elaine M Hylek
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

Review 6.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

7.  Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Authors:  B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

8.  Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg
Journal:  Trials       Date:  2010-11-17       Impact factor: 2.279

9.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
  9 in total
  20 in total

1.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

Review 2.  Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Authors:  Aditi Shendre; Chrisly Dillon; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2018-10-22       Impact factor: 2.533

3.  VKORC1 ER mislocalization causes rare disease.

Authors:  Wade D Van Horn
Journal:  Blood       Date:  2014-08-21       Impact factor: 22.113

4.  3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.

Authors:  G Morgan Jones; Michael J Erdman; Keaton S Smetana; Kerry M Mohrien; Joseph E Vandigo; Lucas Elijovich
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 5.  The future of inpatient anticoagulation management.

Authors:  Allison E Burnett; Toby C Trujillo
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

6.  How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.

Authors:  Kyunghoon Lee; Hye In Woo; Oh Young Bang; Young-Keun On; June Soo Kim; Soo-Youn Lee
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 7.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

8.  VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.

Authors:  Mohamed Hossam A Shahin; Larisa H Cavallari; Minoli A Perera; Sherief I Khalifa; Anne Misher; Taimour Langaee; Shitalben Patel; Kimberly Perry; David O Meltzer; Howard L McLeod; Julie A Johnson
Journal:  Thromb Haemost       Date:  2013-03-21       Impact factor: 5.249

Review 9.  Personalized medicine in thrombosis: back to the future.

Authors:  Srikanth Nagalla; Paul F Bray
Journal:  Blood       Date:  2016-02-04       Impact factor: 22.113

10.  A Retrospective Comparison of 3-Factor Prothrombin Complex Concentrate Products for Warfarin Reversal.

Authors:  G Morgan Jones; Brandon Cave; Ryan Cook
Journal:  Neurohospitalist       Date:  2020-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.